CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 6 enrolled
Drug / intervention
Regadenoson +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02389738
NCT02389738Early Ph 1Completed

Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Mar 17, 2015·Updated Nov 20, 2018

In Brief

A Early Phase 1 clinical trial evaluating Regadenoson, Temozolomide, and 1 other intervention for Blood Brain Barrier Defect. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The blood-brain barrier (BBB) is an intricate barrier composed of a variety of efflux pumps, a luminal negative charge, a basal lamina and three distinct cell types: brain endothelial cells, pericytes, and astrocyte foot processes. Specifically, the BBB integrity and degree of permeability is regulated by the capillary endothelial cells in response to astrocytic signals. The strength of intercellular junctions (ex. tight junctions, adherins) amongst endothelial cells also plays a major role in permeability. Therefore, modulation of all these paracellular properties may decrease BBB integrity and thus improve drug penetration to the tumor bed. Previous studies utilizing the vasoactive peptide, Regadenoson, demonstrated transient increase in BBB permeability, allowing a 70kD dextran molecule to enter the brain of rodents. Thus, the investigators propose to evaluate brain interstitium concentrations of temozolomide pre and post Regadenoson using brain microdialysis. If Regadenoson successfully demonstrates effectiveness in disrupting the BBB, it could be of major importance in improving the outcome of patients with a variety of brain tumors and other neurologic illnesses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartFeb 1, 2015
Primary CompletionFeb 1, 2016
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.3 years ago

Interventions

Regadenosondrug

Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

Temozolomidedrug

Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

Microdialysis catheterdevice

Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.